In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cook Urological Inc.

Division of Cook Group Inc.
www.cookmedical.com/uro/home.do

Latest From Cook Urological Inc.

Percutaneous Systems Inc. (PercSys)

Stone disease is among the most painful and prevalent of urologic disorders, affecting more than 5% of the US population. The most common intervention for kidney and ureteral stones involves manipulation, irrigation and fragmentation through an endoscope. However, such procedures may cause the stone itself or stone fragments to migrate within the urinary tract. Current devices to reduce migration are difficult to place and remove, and they do not adequately conform to the ureter. These products also do not provide a fluid-tight seal. In contrast, the PercSys Accordion stone management device from Percutaneous Systems (PercSys) effectively eliminates stone migration and facilitates fragment removal. The microcatheter system forms an occlusion in the ureter to prevent stone migration, has been shown to increase fragmentation efficiency, and has demonstrated its ability to sweep multiple fragments.
Medical Device

Deals Update (09/2007)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

Urology: Redefining the Standards of Care

Serving the aging US demographic is a golden opportunity for urology device companies. However, at this year's meeting of the American Urological Association, the field concentrated more on consolidation of older techniques than on breakthrough technologies.
Medical Device

Cook Group Goes to School in Cell Therapy

While a host of cardiovascular device companies are collaborating with gene and cell therapy firms in heart disease, Cook is taking a different approach to get in-house cell therapy expertise. It's created spin-off Cook Myosite, to develop the first cell therapy for urinary incontinence. Cook's urological division will sell the final product.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cook Group Inc.
  • Senior Management
  • Contact Info
  • Cook Urological Inc.
    Phone: (812) 829-4891
    1100 West Morgan St.
    P.O. Box 4195 Bloomington, IN 47402-4195
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register